Route of admAdministratof BCG for bladder cancer is
**Core Concept**
The question is testing the knowledge of the intravesical administration of BCG (Bacillus Calmette-Guérin) as an immunotherapy agent for the treatment of bladder cancer. Intravesical therapy involves the direct instillation of medications into the bladder to treat superficial bladder cancer.
**Why the Correct Answer is Right**
BCG is a live, attenuated strain of Mycobacterium bovis used to stimulate the immune system to fight cancer cells. The intravesical route involves the instillation of BCG into the bladder through a catheter, allowing the bacteria to interact with the bladder mucosa and induce an immune response against cancer cells. This approach is particularly effective for treating non-muscle-invasive bladder cancer. The correct answer is **intravesical** because it is the standard route of administration for BCG in bladder cancer treatment.
**Why Each Wrong Option is Incorrect**
* **Option A:** is incorrect because intravenous administration would not allow BCG to interact directly with the bladder mucosa, reducing its effectiveness.
* **Option B:** is incorrect because oral administration would not target the bladder specifically, and the bacteria would be digested in the gastrointestinal tract before reaching the bladder.
* **Option C:** is incorrect because topical application would not allow BCG to penetrate the bladder mucosa effectively, reducing its therapeutic efficacy.
**Clinical Pearl / High-Yield Fact**
It is essential to note that intravesical BCG therapy requires careful patient selection, administration, and follow-up to minimize the risk of complications, such as hemorrhagic cystitis.
**Correct Answer:** A. Intravesical